ENDRA Life Sciences Inc. has 6 Schedule 13D or 13G filings on record since 2025-10-28. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| John Carter Lipman | 9.99% | 115,477 | SCHEDULE 13G, 2025-10-30 | 2025-10-23 |
| ATW Master Fund V LP | 9.9% | 116,024 | SCHEDULE 13G, 2025-10-28 | 2025-10-16 |
| Anthony DiGiandomenico | 9.9% | 196,692 | SCHEDULE 13D/A, 2026-06-29 | 2026-06-25 |
| S.H.N. Financial Investments Ltd. | 3% | 35,588 | SCHEDULE 13G/A, 2025-11-14 | 2025-11-14 |
| L1 Capital Global Opportunities Master Fund, Ltd. | 3% | 35,589 | SCHEDULE 13G/A, 2025-11-14 | 2025-11-14 |
Purpose of Transaction (Item 4)
Anthony DiGiandomenico
On June 25, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among ASP Isotopes Inc., a Delaware corporation, Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ASP ("Noble"), Renergen Limited, a company incorporated under the laws of the Republic of South Africa and a direct, wholly-owned subsidiary of ASP , the Issuer, and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Issuer ("Merger Sub"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Noble (the "Merger"), with Noble surviving the Merger as a direct wholly-owned subsidiary of the Issuer. Also on June 25, 2026, in connection with the Merger Agreement, the Issuer, Noble and the Reporting Person entered into a voting agreement (the "Voting Agreement"). Pursuant to the Voting Agreement, the Reporting Person has agreed, among other things, subject to the terms and conditions thereof, to: (i) vote their beneficially owned securities of the Issuer in favor of the approval of (A) the issuance of the shares of Class A Common Stock (as defined below) and Class B Common Stock (as defined below) of the Issuer as consideration in the Merger, (B) the implementation of a reverse stock split for the purpose of maintaining compliance with Nasdaq listing standards, if …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-29; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-28 | ATW Master Fund V LP | 9.9% | SCHEDULE 13G |
| 2025-10-30 | John Carter Lipman | 9.99% | SCHEDULE 13G |
| 2025-11-14 | S.H.N. Financial Investments Ltd. | 3% | SCHEDULE 13G/A |
| 2025-11-14 | L1 Capital Global Opportunities Master Fund, Ltd. | 3% | SCHEDULE 13G/A |
| 2025-11-26 | Anthony DiGiandomenico | 9.99% | SCHEDULE 13D |
| 2026-06-29 | Anthony DiGiandomenico | 9.9% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for ENDRA Life Sciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.